Posturography-Neuropathy (PONE)
Primary Purpose
Neuropathy Demyelinating
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Motion analysis
Sponsored by
About this trial
This is an interventional other trial for Neuropathy Demyelinating focused on measuring Gait, Balance, Posture, Charcot-Marie-Tooth, Chronic inflammatory demyelinating polyneuropathy
Eligibility Criteria
Inclusion Criteria:
- CMT1A for molecular-proven Group 1 (PMP22 duplication)
- IPDC likely or defined for Group 2
- Able to walk 10 m unassisted
Exclusion Criteria:
- Neurological history other than neuropathy: epilepsy, stroke, dementia
- Pregnant women
- Person under guardianship or trusteeship
- Musculoskeletal conditions other than neuropathy impairing walking abilities
- Major comorbidity considered a contraindication by the investigator (cancer, unstable angor, etc.)
Sites / Locations
- Hôpital Roger Salengro, CHURecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
demyelinating hereditary neuropathy
demyelinating inflammatory neuropathy
Arm Description
adult patients with demyelinating hereditary neuropathy type CMT 1A.
adult patients with acquired demyelinating inflammatory neuropathy.
Outcomes
Primary Outcome Measures
Posturography (Romberg's quotient)
Secondary Outcome Measures
The Timed Up and Go test (TUG)
It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
the scores of ten seconds or less indicate normal mobility, 11-20 seconds are within normal limits for frail elderly and disabled patients, and greater than 20 seconds means the person needs assistance outside and indicates further examination and intervention. A score of 30 seconds or more suggests that the person may be prone to falls
stride length (in millimeters) parameters
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
stride time (in seconde) parameters
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
velocity (meter/seconde) parameters
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
cadence (step/min) parameters
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
Full Information
NCT ID
NCT04154540
First Posted
August 14, 2019
Last Updated
February 7, 2023
Sponsor
University Hospital, Lille
1. Study Identification
Unique Protocol Identification Number
NCT04154540
Brief Title
Posturography-Neuropathy
Acronym
PONE
Official Title
Study of Gait and Posture in Subacute Acquired Neuropathies and in Hereditary Neuropathies
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 19, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
If the classification between hereditary and acquired neuropathy is often easy, there is no completely specific marker allowing the distinction between the two etiologies. Clinical experience suggests that hereditary neuropathies have less impact on balance and gait than the acquired neuropathies at equivalent level of impairment, but this has never been clearly demonstrated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuropathy Demyelinating
Keywords
Gait, Balance, Posture, Charcot-Marie-Tooth, Chronic inflammatory demyelinating polyneuropathy
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
52 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
demyelinating hereditary neuropathy
Arm Type
Experimental
Arm Description
adult patients with demyelinating hereditary neuropathy type CMT 1A.
Arm Title
demyelinating inflammatory neuropathy
Arm Type
Experimental
Arm Description
adult patients with acquired demyelinating inflammatory neuropathy.
Intervention Type
Other
Intervention Name(s)
Motion analysis
Intervention Description
Gait and posture recording
Primary Outcome Measure Information:
Title
Posturography (Romberg's quotient)
Time Frame
Time 0 ; single session
Secondary Outcome Measure Information:
Title
The Timed Up and Go test (TUG)
Description
It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.
the scores of ten seconds or less indicate normal mobility, 11-20 seconds are within normal limits for frail elderly and disabled patients, and greater than 20 seconds means the person needs assistance outside and indicates further examination and intervention. A score of 30 seconds or more suggests that the person may be prone to falls
Time Frame
Time 0 ; single session
Title
stride length (in millimeters) parameters
Description
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
Time Frame
Time 0 ; single session
Title
stride time (in seconde) parameters
Description
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
Time Frame
Time 0 ; single session
Title
velocity (meter/seconde) parameters
Description
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
Time Frame
Time 0 ; single session
Title
cadence (step/min) parameters
Description
Kinematic and Kinetic parameters of the gait initiation and the stabilised gait using the optoelectronic system (VICON®)
Time Frame
Time 0 ; single session
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
CMT1A for molecular-proven Group 1 (PMP22 duplication)
IPDC likely or defined for Group 2
Able to walk 10 m unassisted
Exclusion Criteria:
Neurological history other than neuropathy: epilepsy, stroke, dementia
Pregnant women
Person under guardianship or trusteeship
Musculoskeletal conditions other than neuropathy impairing walking abilities
Major comorbidity considered a contraindication by the investigator (cancer, unstable angor, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Céline TARD, MD
Phone
0320445765
Ext
+33
Email
celine.tard@chru-lille.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Céline TARD, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Roger Salengro, CHU
City
Lille
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Céline TARD, MD
12. IPD Sharing Statement
Learn more about this trial
Posturography-Neuropathy
We'll reach out to this number within 24 hrs